ReviewFrontiers in immunology2025
Neutrophils in inflammatory bowel disease: disease-promoting versus protective functions.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Macrophage SELENOP controls neutrophil homeostasis through redox stress regulation in Crohn's disease.Redox biology · 2026Article
- METTL3 loss exacerbates colitis via mActa pharmacologica Sinica · 2026Article
- Review
- From uric acid to tophi: multistage molecular and cellular mechanisms of tophi formation.Frontiers in immunology · 2026Review
- Microbiota-innate immune crosstalk drives atherosclerosis: mechanisms, disease progression, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is a complex chronic intestinal inflammatory disorder whose pathogenesis involves aberrant interactions between genetic, environmental, microbial, and immune factors. Neutrophils, as key effector cells of innate immunity, are among the first immune cells to infiltrate the inflamed mucosa in IBD, and their role in the disease course is multifaceted. This review systematically elaborates on the dual functions of neutrophils in IBD. On one hand, activated neutrophils act as crucial "destroyers" promoting the initiation and progression of IBD by releasing effector molecules such as reactive oxygen species (ROS), proteases, and neutrophil extracellular traps (NETs), which disrupt the intestinal epithelial barrier, amplify the inflammatory cascade, promote thrombosis, and mediate resistance to corticosteroids and biologics. On the other hand, neutrophils also play key protective roles by efficiently clearing pathogens and apoptotic cells, secreting pro-angiogenic and tissue repair factors, modulating the stem cell microenvironment, and maintaining microbial homeostasis, thereby actively promoting mucosal healing and inflammation resolution. This article also delves into neutrophil heterogeneity, functional plasticity, and their complex interactions with the microbiota, and proposes new precision therapeutic strategies targeting neutrophils. A comprehensive understanding of the dynamic balance and regulatory mechanisms of this "dual-role guardian" will provide new perspectives for researching IBD pathogenesis and innovating treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.